SOPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SOPHiA GENETICS SA (SOPH) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company shows strong revenue growth, positive analyst sentiment, and a promising partnership with Mount Sinai Health System, which could drive future growth. Despite insider selling, hedge fund buying and technical indicators suggest bullish momentum.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 70.45, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels, with resistance at R1: 5.192 and R2: 5.353. The pre-market price of $5.13 is above the pivot of 4.933, further supporting a bullish trend.
Partnership with Mount Sinai Health System to utilize SOPHiA DDM™ platform for cancer research and genomic testing.
Hedge fund buying has increased significantly by 1033.12% over the last quarter.
Revenue growth of 22.41% YoY in Q4 2025, indicating strong business momentum.
Insider selling has increased by 1960.38% over the last month.
Gross margin dropped slightly by -0.84% YoY in Q4 2025.
In Q4 2025, revenue increased by 22.41% YoY to $21.7M. Net income improved by 26.53% YoY but remains negative at -$19.18M. EPS increased by 21.74% YoY to -0.28. Gross margin slightly declined to 67.68%, down -0.84% YoY.
Analysts are bullish on SOPH. BTIG recently raised the price target to $8 from $7, citing management's confidence in the business. Guggenheim also raised the price target to $7 from $6, reflecting optimism in the company's growth potential.
